<DOC>
	<DOCNO>NCT00070486</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , carboplatin gemcitabine , work different way stop tumor cell divide stop grow die . Celecoxib zileuton may stop growth tumor cell stop blood flow tumor may block enzyme necessary tumor cell growth . Combining chemotherapy celecoxib and/or zileuton may kill tumor cell . PURPOSE : Randomized phase II trial study effectiveness combine celecoxib and/or zileuton carboplatin gemcitabine treat patient advance non-small cell lung cancer .</brief_summary>
	<brief_title>Carboplatin Gemcitabine Combined With Celecoxib and/or Zileuton Treating Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare efficacy carboplatin gemcitabine celecoxib and/or zileuton , term 7-month progression-free survival , patient advance non-small cell lung cancer . Secondary - Compare response rate , distribution survival , failure-free survival time patient treat regimen . - Correlate CYFRA serum vascular endothelial growth factor level response survival patient treat regimen . - Correlate cyclo-oxygenase-2 5-lipoxygenase expression survival patient treat regimen . OUTLINE : This randomize , multicenter study . Patients randomize 1 3 treatment arm . - Arm I : Patients receive gemcitabine IV 30 minute day 1 8 , carboplatin IV 30 minute day 1 , oral zileuton 4 time daily day 1-21 . - Arm II : Patients receive gemcitabine carboplatin arm I oral celecoxib twice daily day 1-21 . - Arm III : Patients receive gemcitabine carboplatin arm I , oral celecoxib arm II , oral zileuton arm I . In arm , treatment repeat every 21 day 6 course . Patients respond stable disease continue course zileuton and/or celecoxib absence disease progression unacceptable toxicity . Patients follow monthly 1 year , every 2 month 2 year , every 4 month 3 year disease progression . PROJECTED ACCRUAL : A total 117 patient ( 39 per treatment arm ) accrue study within 11-12 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Zileuton</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer ( NSCLC ) 1 follow cellular type : Adenocarcinoma Large cell Squamous cell Mixed Meets 1 follow stag criterion : Stage IIIB disease malignant pleural effusion , supraclavicular node involvement , contralateral hilar node Stage IIIB patient eligible Cancer Leukemia Group B protocol combine chemotherapy chest irradiation allow Stage IV disease Measurable nonmeasurable disease Unidimensionally measurable lesion least 20 mm conventional technique OR least 10 mm spiral CT scan The following consider nonmeasurable disease : Bone lesion Ascites Pleural/pericardial effusion Lymphangitis cutis/pulmonis Abdominal mass confirm followed imaging technique Cystic lesion Small lesions No leptomeningeal disease Symptomatic CNS metastases must treat ( e.g. , surgery , radiotherapy , gamma knife ) , neurologically stable , steroids PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 1.5 mg/dL AST great 2.0 time upper limit normal Renal Creatinine great 1.5 mg/dL Cardiovascular None follow within past 6 month : Myocardial infarction Unstable angina Symptomatic congestive heart failure Serious uncontrolled cardiac arrhythmia Cerebrovascular accident Transient ischemic attack Symptomatic carotid artery peripheral vascular disease Deep vein thrombosis Significant thromboembolic event Pulmonary No pulmonary embolism within past 6 month Gastrointestinal No history gastrointestinal ( GI ) bleed No history peptic ulcer disease No active GI bleed Other Not pregnant nursing No know hypersensitivity aspirin , NSAIDs , sulfonamides No currently active second malignancy nonmelanoma skin cancer Patients consider currently active malignancy complete therapy consider physician less 30 % risk relapse PRIOR CONCURRENT THERAPY : Biologic therapy No prior immunotherapy NSCLC Chemotherapy No prior chemotherapy NSCLC No concurrent chemotherapy Endocrine therapy See Disease Characteristics No concurrent chronic oral steroid Concurrent episodic steroid antiemetic purpose allow No concurrent hormonal therapy Concurrent inhale steroid allow medically indicated Concurrent megestrol appetite stimulation allow Radiotherapy See Disease Characteristics At least 2 week since prior radiotherapy recover Surgery See Disease Characteristics At least 2 week since prior surgery recover Other No prior systemic treatment NSCLC No concurrent investigational therapy At least 1 week since prior nonsteroidal antiinflammatory drug ( NSAIDs ) , include follow : Rofecoxib Choline magnesium trisalicylate Ibuprofen Naproxen Etodolac Oxaprozin Diflunisal Nabumetone Tolmetin Valdecoxib No concurrent NSAIDs No concurrent chronic aspirin Concurrent aspirin great 325 mg/day allow No concurrent fluconazole No concurrent leukotriene antagonist ( e.g. , zafirlukast , montelukast , pranlukast )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>